The proteasome inhibitor bortezomib (BTZ, also known as Velcade) is currently in use for the treatment of multiple myeloma (Field-Smith et al., 2006), and we tested whether this inhibitor was also able to restore expression levels of mutant bestrophin-1. The gene discussed is BEST1; the disease is plasma cell myeloma.